TY - JOUR
T1 - Advances in IgE Testing for Diagnosis of Allergic Disease
AU - Hamilton, Robert G.
AU - Hemmer, Wolfgang
AU - Nopp, Anna
AU - Kleine-Tebbe, Jörg
N1 - Funding Information:
Conflicts of interest: W. Hemmer has received nonfinancial support from Thermo Fisher Scientific ; and personal fees from MacroArray Diagnostics, outside the submitted work. J. Kleine-Tebbe reports personal fees from AllergenOnline (Nebraska, USA), Allergy Therapeutics, Allergopharma, ALK-Abelló, AstraZeneca, Bencard, Dr. Pfleger, HAL Allergy, InfectoPharm, LETI, Merck US, Sanofi Genentech, Springer International Publishers, ThermoFisher Scientific, and Thieme Publishers, Germany; has received grants and personal fees from GSK , Lofarma , Novartis , and Stallergenes-Greer ; has received nonfinancial support from American Academy of Allergy Asthma and Immunology , European Academy of Allergy and Clinical Immunology , and World Health Organization / International Union of Immunological Societies Allergen nomenclature subcommittee ; and has received personal fees and nonfinancial support from the German Society of Allergy and Clinical Immunology ; all outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest.
Funding Information:
Conflicts of interest: W. Hemmer has received nonfinancial support from Thermo Fisher Scientific; and personal fees from MacroArray Diagnostics, outside the submitted work. J. Kleine-Tebbe reports personal fees from AllergenOnline (Nebraska, USA), Allergy Therapeutics, Allergopharma, ALK-Abell?, AstraZeneca, Bencard, Dr. Pfleger, HAL Allergy, InfectoPharm, LETI, Merck US, Sanofi Genentech, Springer International Publishers, ThermoFisher Scientific, and Thieme Publishers, Germany; has received grants and personal fees from GSK, Lofarma, Novartis, and Stallergenes-Greer; has received nonfinancial support from American Academy of Allergy Asthma and Immunology, European Academy of Allergy and Clinical Immunology, and World Health Organization/International Union of Immunological Societies Allergen nomenclature subcommittee; and has received personal fees and nonfinancial support from the German Society of Allergy and Clinical Immunology; all outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest. No funding was received for this work.
Publisher Copyright:
© 2020
PY - 2020/9
Y1 - 2020/9
N2 - Since its discovery in 1967, IgE antibody detection in skin and blood has identified a state of allergic sensitization and served as a necessary but not sufficient risk factor that requires objective symptoms to make the definitive diagnosis of human allergic disease. More recently, quantitative IgE antibody levels in serum against allergenic extracts, molecules, and epitopes have pushed its application into more accurately identifying the specificity of the allergic response for targeting immunotherapy, predicting allergic symptom severity after allergen exposure, and attempting to distinguish tolerance from food allergy. This review examines new in vivo and in vitro developments in the design, performance, interference, and application of the methods used to identify allergic sensitization. The increasing accepted applications of molecular allergen and allergen epitope-based IgE antibody measurements, especially as applied to food allergy diagnosis and management, are highlighted as state-of-the-art advances. Despite these major advances in allergic sensitization documentation, their ultimate value requires integration by the clinician with the patient's history and pretest probability of disease.
AB - Since its discovery in 1967, IgE antibody detection in skin and blood has identified a state of allergic sensitization and served as a necessary but not sufficient risk factor that requires objective symptoms to make the definitive diagnosis of human allergic disease. More recently, quantitative IgE antibody levels in serum against allergenic extracts, molecules, and epitopes have pushed its application into more accurately identifying the specificity of the allergic response for targeting immunotherapy, predicting allergic symptom severity after allergen exposure, and attempting to distinguish tolerance from food allergy. This review examines new in vivo and in vitro developments in the design, performance, interference, and application of the methods used to identify allergic sensitization. The increasing accepted applications of molecular allergen and allergen epitope-based IgE antibody measurements, especially as applied to food allergy diagnosis and management, are highlighted as state-of-the-art advances. Despite these major advances in allergic sensitization documentation, their ultimate value requires integration by the clinician with the patient's history and pretest probability of disease.
KW - Allergen
KW - Human
KW - IgE antibody
KW - Microarray
KW - Molecule-based allergy diagnosis
KW - Multiplex
KW - Performance
KW - Quality assurance
KW - Serodiagnosis
KW - Singleplex
KW - Type 1 hypersensitivity
UR - http://www.scopus.com/inward/record.url?scp=85089913389&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089913389&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2020.07.021
DO - 10.1016/j.jaip.2020.07.021
M3 - Article
C2 - 32717438
AN - SCOPUS:85089913389
VL - 8
SP - 2495
EP - 2504
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
SN - 2213-2198
IS - 8
ER -